乳腺癌蒽环类化疗中应用心脏CT连续评估冠状动脉炎症
该研究对14例乳腺癌患者蒽环类治疗前及治疗后3、6、12个月共四次冠状动脉CTA的冠周脂肪衰减指数(FAI)进行事后分析,FAI(Total)从基线-77.3±5.6 HU逐渐升高至12个月-73.8±5.8 HU,12个月较基线显著升高(p<0.001),提示FAI可能作为冠状动脉炎症的影像生物标志物。
要点
- 乳腺癌蒽环类化疗后3、6、12个月FAI(Total)较基线逐渐升高
- 12个月FAI(Total)较基线显著升高(p<0.001)
- 全部14例患者均出现轻度无症状的癌症治疗相关心功能障碍
核心结论
- 乳腺癌患者蒽环类治疗后3、6、12个月FAI较治疗前逐渐升高,12个月时较基线显著升高(p<0.001)。
- FAI可能作为蒽环类治疗随访中冠状动脉炎症的影像生物标志物,并可能通过早期检测冠状动脉毒性促进个体化治疗。
研究设计与样本
- 前瞻性研究的事后分析,纳入2019年8月至2020年7月期间接受蒽环类治疗的乳腺癌患者。
- 最终分析14例CT图像质量合格的患者,平均年龄62岁±11(标准差),均为女性。
- 在蒽环类治疗前及治疗后3、6、12个月共四次冠状动脉CTA扫描中量化FAI,取三支冠状动脉FAI平均值计算FAI(Total)。
关键影像表现/征象
- FAI(Total)在观察期内较基线逐渐升高:基线-77.3±5.6 HU,3个月-77.1±4.8 HU,6个月-76.5±5.4 HU,12个月-73.8±5.8 HU。
- 12个月FAI(Total)较基线显著升高(p<0.001)。
诊断标准与关键数值
- FAI(Total)定义为三支冠状动脉FAI的平均值,基于冠状动脉CTA图像量化。
- 观察期内全部14例接受蒽环类治疗的患者均出现与癌症治疗相关的轻度无症状心功能障碍(CTRCD)。
临床应用与阅片要点
- 在乳腺癌蒽环类化疗患者的冠状动脉CTA随访中,可定量FAI(Total)以观察其动态变化。
- FAI(Total)于治疗后3、6、12个月较基线逐渐升高,12个月时升高达统计学显著。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: There is limited evidence of the pericoronary fat attenuation index (FAI) as an imaging marker to assess cancer therapy-related cardiovascular toxicity. We aimed to measure FAI in four consecutive coronary CT angiography (CTA) scans before and 3, 6, and 12 months after anthracycline treatment in patients with breast cancer to determine trends in dynamic changes in FAI after treatment.
METHODS: We performed a post hoc analysis of a prospective study (between August 2019 and July 2020) in which anthracycline-induced myocardial injury was evaluated using cardiac CT. FAI was quantified using coronary CTA images before and 3, 6, and 12 months after anthracycline treatment. The FAIs of the three coronary arteries were averaged to calculate the FAI (Total).
RESULTS: FAI was analyzed on 14 patients with breast cancer who had adequate CT image quality (mean age, 62 years ± 11 (SD); 14 women). During the observation period, all 14 patients treated with anthracycline developed mild asymptomatic cardiac dysfunction related to cancer treatment (CTRCD). FAI (Total) showed a gradual increase during the observation period compared to baseline (baseline: -77.3 ± 5.6 HU, 3 months: -77.1 ± 4.8 HU, 6 months: -76.5 ± 5.4 HU, 12 months: -73.8 ± 5.8 HU). FAI (Total) was significantly elevated at 12 months compared to baseline (p < 0.001).
CONCLUSION: In patients with breast cancer, FAI showed a gradual increase at 3, 6, and 12 months after treatment with anthracyclines compared to before treatment. FAI may be used as an imaging biomarker of coronary artery inflammation in the follow-up of anthracycline therapy and may contribute to the personalization of therapy through early detection of coronary toxicity.
KEY POINTS: Question Is pericoronary fat attenuation index (FAI) a potential imaging biomarker for assessing changes in pericoronary adipose tissue related to cancer therapy-related cardiovascular toxicity? Findings In 14 patients with breast cancer, FAI showed a gradual increase at 3, 6, and 12 months after treatment with anthracyclines compared to before treatment. Clinical relevance FAI may be an imaging biomarker for the detection and treatment of cancer therapy-related cardiovascular toxicity.
引用
- Kidoh M, Oda S, Sueta D, et al. Serial assessment of coronary artery inflammation using cardiac CT in anthracycline chemotherapy for breast cancer. Eur Radiol. 2025. PMID: 39838089. doi:10.1007/s00330-025-11347-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。